Showing results (291-300 of 548) with videos related to
Sort By:
Pageof 55
Journal of the American Academy of Dermatology|October 16, 2016
Ten-year mortality is increased after hospitalization for atopic dermatitis compared with the general population, but reduced compared with psoriasisAlexander Egeberg, Lone Skov, Yuki M F Andersen, et al.Journal of the American Academy of Dermatology|August 16, 2019
Psoriasis and mortality in the United States: Data from the National Health and Nutrition Examination SurveyYevgeniy R Semenov, Christina M Herbosa, Andrew T Rogers, et al.Frontiers in Pediatrics|September 25, 2024
Dupilumab treatment reduces caregiver-reported skin pain in patients with moderate-to-severe atopic dermatitis aged 6 months to 5 yearsAmy S Paller, Jonathan I Silverberg, Mercedes E Gonzalez, et al.JAMA Dermatology|May 26, 2021
Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin DiseasesMaria C Schneeweiss, Seoyoung C Kim, Richard Wyss, et al.Dermatology and Therapy|November 4, 2023
Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative ReviewAndrew Blauvelt, Richard G Langley, Kenneth B Gordon, et al.American Journal of Clinical Dermatology|April 7, 2021
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical TrialsBrett King, Catherine Maari, Edward Lain, et al.Dermatology and Therapy|October 23, 2018
Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their FamiliesEric L Simpson, Amy S Paller, Mark Boguniewicz, et al.Dermatology and Therapy|November 30, 2021
Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16Jonathan I Silverberg, Mark Boguniewicz, Jill Waibel, et al.Dermatology and Therapy|August 6, 2022
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b TrialMelinda J Gooderham, Giampiero Girolomoni, Julian O Moore, et al.Journal of Drugs in Dermatology : JDD|February 2, 2024
Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic DermatitisLawrence F Eichenfield, Jonathan I Silverberg, Adelaide A Hebert, et al.Pageof 55